biointron_weekly

Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules designed to degrade specific proteins by recruiting an E3 ubiquitin ligase to the target protein, leading to its ubiquitylation and subsequent degradation by the proteasome. This novel mechanism enables PROTACs to eliminate on

Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected mosquitoes. Of the five species of Plasmodium that cause malaria, Plasmodium falciparum is the deadliest, responsible for the majority of cases and deaths, particularly in Africa, where young children are

Alzheimer’s research has undergone transformative changes in recent years, characterized by breakthroughs, controversies, and a reevaluation of long-held theories. Recently, BioArctic announced a global license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-

The FDA has revoked Emergency Use Authorizations (EUAs) for multiple COVID-19 monoclonal antibody (mAb) therapies, including those developed by Eli Lilly, AstraZeneca, Vir Biotechnology, and Regeneron. This decision reflects the challenges of targeting rapidly mutating viruses like SARS-CoV-2, which

Antibody drugs offer targeted and effective therapies for inflammatory conditions such as chronic diseases like rheumatoid arthritis, Crohn's disease, and psoriasis. By specifically binding to pro-inflammatory cytokines or their receptors, monoclonal antibodies help modulate the immune response,

Biparatopic antibodies (bpAbs) are bispecific antibodies which bind distinct, non-overlapping epitopes on an antigen. This unique binding mode allows for superior affinity and specificity, promotes antagonism, locks target conformation, and results in higher-order target clustering. The antibody-target complexes can elicit strong agonism, increase immune effector function, or result in rapid target downregulation and lysosomal trafficking.

This month, two high-profile deals for bispecific antibodies targeting the PD-1/PD-L1 and VEGF pathways were announced. The DealsOn November 14, Merck announced its licensing agreement with LaNova Medicines for LM-299, an investigational PD-1/VEGF bispecific antibody. Merck is committing up to

Respiratory Syncytial Virus (RSV) is a leading cause of severe respiratory infections, particularly in infants, the elderly, and immunocompromised individuals. Despite its global prevalence, there has historically been a lack of effective therapeutic options for high-risk populations.

Discover the latest insights on antibody drug reliability, addressing aggregation, impurities, and stability challenges in biomedical research for improved outcomes.

This week, computationally designed antibody therapeutics have been high on the news, leveraging advanced deep learning and AI-driven methodologies to accelerate the discovery and optimization of antibodies.

Anti-amyloid antibodies are designed to target and remove amyloid-beta plaques in the brain, a hallmark of Alzheimer’s disease. These plaques are toxic protein clusters believed to disrupt communication between neurons, leading to cell death and cognitive decline. By binding to amyloid-beta, these antibodies aim to neutralize or clear the plaques, potentially slowing disease progression.

Recently, we have seen exciting developments in the antibody-drug conjugate (ADC) space, from cloud computing to radioisotopes.

This past week, the Biomedical Advanced Research and Development Authority (BARDA) has provided funding for several antibody-related drug development programs. BARDA is a U.S. government agency within the Department of Health and Human Services (HHS) that funds and supports the development of medical countermeasures to protect against public health threats, such as pandemics, bioterrorism, and other emergencies.

Antibody-drug conjugates (ADCs) have seen significant developments in regulatory review, with several notable announcements in the past few weeks. Innate Pharma received FDA clearance for its investigational new drug (IND) application for IPH4502, a novel topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4. Nectin-4 is a cell membrane adhesion protein overexpressed in several solid tumors, including urothelial, breast, esophageal, lung, ovarian, and pancreatic cancers, with limited expression in normal tissues.